A new variant of the COVID-19 virus, known as KP.2, has emerged as the dominant strain in the United States, accounting for more than a third of all cases. This fast-growing member of the FLiRT variants, along with another strain called KP.1.1, now make up a projected 35.3% of COVID-19 infections in the country.
Despite its prevalence, health experts have stated that KP.2 does not have significant changes that would cause an increase in infections or lead to more severe illness. The Food and Drug Administration has postponed the selection of the strain to target for the upcoming fall’s COVID-19 vaccines due to the rapid evolution of circulating variants.
KP.2 is closely related to the JN.1 variant from the previous winter and is being closely monitored by health authorities. While the FLiRT nickname for these variants comes from unique mutations in the virus’ spike protein, experts have downplayed claims that variants result in different symptoms, although potential changes in immunity have been acknowledged.
Pfizer has conducted research on its vaccines against KP.2, and Novavax has announced that its vaccine candidate aimed at JN.1 has good cross-reactivity for KP.2. Although the CDC has not altered its vaccine recommendations, the emergence of KP.2 may impact vaccine selection for the fall.
Overall, while the dominance of the KP.2 variant is noted in the U.S., health officials are closely monitoring the situation and working to ensure that vaccines remain effective against the evolving strains of the virus. Stay tuned to Matzav Blog for more updates on COVID-19 developments.
